AR Degrader-3
AR Degrader-3 is an orally active molecular glue that targets AR/ARV7 and induces the degradation of AR and ARV7 through the ubiquitin-proteasome pathway (UPP). AR Degrader-3 directly interacts with the ligand-binding domain (LBD) and the N-terminal domain (NTD) of AR. AR Degrader-3 effectively suppresses the transcriptional activity of wild-type AR (AR-WT), AR mutants, and ARV7. AR Degrader-3 downregulates the mRNA and protein levels of downstream AR target genes, thereby overcoming antiandrogen resistance mediated by ARV7 and AR point mutations. AR Degrader-3 induces apoptosis in Enzalutamide (HY-70002) (ENZa)-resistant cells and increases cleaved caspase-3 protein levels. AR Degrader-3 can be used for the study of castration-resistant prostate cancer (CRPC).
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 1182011-65-9
- Formel: C23H21N3O4S
- Molecular Weight:435.50
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Alle Caspase Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
|
Caspase-3 |
AR Degrader-3 (Compound A6) (0.2-5 μM, 24 h) broadly inhibits AR transcriptional activity by dose-dependently suppressing both exogenous and endogenous AR in PC-3 and C4-2 cells; additionally, it significantly suppresses endogenous AR and ARV7 in ENZa-resistant 22Rv1 cells, and inhibits the transcriptional activities of AR mutants (W741L, T877A, F876L) in PC-3 cells[1].
AR Degrader-3 (0.078-10 μM, 0-36 h) dose-dependently suppresses ARV7 (DC50 = 0.24 μM) protein level in 22Rv1 cells, powerfully down-regulates AR (DC50 = 0.18 μM) protein level in C4-2 cells, and down-regulates ARV7 protein levels in a time-dependent manner[1].
AR Degrader-3 potently inhibits AR and ARV7 by directly binding to both AR-LBD (IC50 = 105.4 nM) and AR-AF1 (KD = 23.0 μM ) in LNCaP cells[1].
AR Degrader-3 (1-5 μM, 4-8 h) degrades AR and ARV7 through the ubiquitin-proteasome pathway (UPP), as evidenced by its dose-dependent reduction of AR and ARV7 protein but not mRNA levels in C4-2 and 22Rv1 cells, respectively; by demonstrating accelerated degradation upon cycloheximide treatment; by showing that the protein level reduction was counteracted by MG132; and by markedly inducing AR ubiquitination[1].
AR Degrader-3 (72 h) inhibits the proliferation of C4-2 cells (IC50 = 0.59 μM) and 22Rv1 cells (IC50 = 1.4 μM), but has little effect on DU145 (IC50 > 50 μM) and PC-3 (IC50 = 48.6 μM) cells[1].
AR Degrader-3 (0.2-5 μM, 8-24 h) blocks R1881-induced PSA protein expression in a dose-dependent manner and reduces the mRNA levels of PSA and PMEPA1 in 22Rv1 cells[1].
AR Degrader-3 (1-2 μM, 14 days) selectively decreases 22Rv1 cells colony numbers but shows no influence on AR-negative PC-3 cells colony numbers and promotes the apoptosis of the 22Rv1 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:22Rv1 cells
-
Concentration:5 μM
-
Incubation Time:24 h
-
Result:Significantly downregulated the level of ARV7.
-
Cell Line:22Rv1 cells, C4-2 cells
-
Concentration:0.078 μM, 0.156 μM, 0.31 μM, 0.62 μM, 1.25 μM, 2.5 μM, 5 μM, 10 μM
-
Incubation Time:24 h
-
Result:Dose-dependently suppressed ARV7 (DC50 = 0.24 μM) protein level in 22Rv1 cells, down-regulated AR (DC50 = 0.18 μM) protein level in C4-2 cells.
-
Cell Line:22Rv1 cells
-
Concentration:0.2 μM, 1 μM, 5 μM
-
Incubation Time:24 h
-
Result:Blocked R1881-induced PSA protein expression in a dose-dependent manner in 22Rv1 cells.
-
Cell Line:22Rv1 cells
-
Concentration:0.2 μM, 1 μM, 5 μM
-
Incubation Time:8 h
-
Result:Reduced the mRNA level of PSA in 22Rv1 cells.
-
Cell Line:22Rv1 cells
-
Concentration:0.2 μM, 1 μM, 5 μM
-
Incubation Time:24 h
-
Result:Reduced the mRNA level of PMEPA1 in 22Rv1 cells.
-
Cell Line:22Rv1 cells, PC-3 cells
-
Concentration:1 μM, 2 μM
-
Incubation Time:14 days
-
Result:Decreased 22Rv1 cells colony numbers but showed no influence on AR-negative PC-3 cells colony numbers.
| Species | Dose | Route | CL | T1/2 | AUC | Tmax | Cmax | F |
|---|---|---|---|---|---|---|---|---|
| Mice | 1.9 mg/kg | i.v. | 2.17 L/h/kg | 0.73 h | 879 ng·h/mL | / | / | / |
| Mice | 10 mg/kg | p.o. | / | 2.65 h | 657 ng·h/mL | 0.67 h | 178 ng/mL | 13.1 % |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male BALB/c nude mice (5-week-old) were subcutaneously inoculated with 5 × 106 22Rv1 cells[1].
-
Dosage:15 mg/kg, 30 mg/kg
-
Administration:P.o., once daily for 14 days
-
Result:Suppressed 22Rv1 tumor progression.
Showed no change in body weight.
Significantly decreased AR levels in the tumor tissues.
Chemical Information
-
CAS. Nr. 1182011-65-9
-
Molecular Weight 435.50
-
Formel C23H21N3O4S
-
SMILES
CC1=NOC(C)=C1COC2=CC=C(C(NC3=NC(C4=CC=C(OC)C=C4)=CS3)=O)C=C2
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)